With the legalization of cannabis in more countries and states, the illicit market will continue to decline while the medical and health market will continue to expand. In Canada alone, the total addressable cannabis market represented $6.81 billion in 2018 and is projected to reach $7.7 billion by 2025. (source: New Frontier Data, 2018)

Among the many markets increasingly open to Allied’s targeted cannabinoid products are:

  • Pharma products
  • Natural health products
  • Edibles
  • Topicals
  • Cannabis
  • Electrolyte replacement athletic recovery drinks

While all of-age individuals are potential consumers for Allied’s products, one of our top R&D priorities is on Post Traumatic Stress Injury (PTSI) solutions that will provide a direct and specialized inroad to the multitude of PTSI sufferers around the world.

Market Case Study: Canada

On October 17, 2018, The Cannabis Act came into force in Canada.

The act replaced Canada’s previous Access to Cannabis for Medical Purposes Regulations (ACMPR), making changes designed to improve patient access.

The act also legalized recreational cannabis.

The following research underscores the rapid and significant market growth associated with a population looking to cannabinoid solutions for targeted medical support and overall wellbeing.

Sign up to our newsletter and receive latest investor news, events, and other important information related to Allied Health.

Keep Informed